Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2008

View Archived Issues

Hsp90 inhibitors demonstrate antitumor effects in preclinical studies

Novel inhibitor of tyrosine kinases shows antitumor activity in preclinical models

MI-219 displays preclinical anticancer activity

AEterna Zentaris develops new cytotoxic conjugate, AEZS-125

FDA approves Calando's IND application for siRNA nanoparticle therapeutic CALAA-01

Cosmo reports positive results from phase IIb trial of Heparin MMX for ulcerative colitis

Actelion and Nippon Shinyaku sign license agreement for NS-304 for PAH

Genentech reports additional positive results from phase III AVAil clinical study of Avastin

Starpharma reports results from studies of VivaGel in genital warts and cervical cancer

Dainippon Sumitomo Pharma launches Lonasen for schizophrenia

Q1 highlights at Gilead Sciences

InterMune to initiate open-label rollover study of pirfenidone in IPF in August 2008

BioAlliance Pharma and Strativa announce phase III study results for Loramyc in OPC

New treatment options for obesity and lipoprotein disorders reported in recent patents

Optimer Pharmaceuticals reveals preliminary data on safety and pharmacokinetics for OPT-80

Angiotech suspends enrollment in U.S. and E.U. human clinical trials for Vascular Wrap

ErepoXen shows positive results from phase I trial

Recent AstraZeneca patent discloses new treatment options for gastrointestinal disorders

Novel agents for neurological disorders described in recent AstraZeneca and Merck Frosst patents

Almirall presents promising results for new asthma and COPD compound

Combination of dutasteride with tamsulosin approved for the treatment of BPH

Inspire discontinues epinastine nasal spray development

Replidyne discontinues phase III faropenem trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...